Clinical Manifestations.

Background: Assessments for early-stage Alzheimer's disease (AD) aim to identify neuropsychological and functional impairments, which rarely correlate with early disease stages. We need to enhance our understanding of the cognitive aspects contributing to functional decline to improve sensitivity in functional assessment. The ability to bind information in memory declines in preclinical AD stages.

Clinical Manifestations.

Background: Recent studies suggest that among cognitively unimpaired older adults, there are individuals who might present with subtle cognitive impairments suggesting the risk of Alzheimer's disease (AD; Bos et al., 2018). The Visual Short-Term Memory Binding Test (VSTMBT) identifies older adults who are accumulating AD pathology even though they are otherwise cognitively unimpaired (Parra et al.

Clinical Manifestations.

Background: Traditional neuropsychological assessments have proved insensitive to identify the preclinical stages of Alzheimer's disease (AD). Such a barrier has proved more challenging when assessing individuals from underrepresented populations (Parra et al., 2018; 2020; 2022).

Promising developments in neuropsychological approaches for the detection of preclinical Alzheimer's disease: a selective review.

Recently published guidelines suggest that the most opportune time to treat individuals with Alzheimer's disease is during the preclinical phase of the disease. This is a phase when individuals are defined as clinically normal but exhibit evidence of amyloidosis, neurodegeneration and subtle cognitive/behavioral decline. While our standard cognitive tests are useful for detecting cognitive decline at the stage of mild cognitive impairment, they were not designed for detecting the subtle cognitive variations associated with this biomarker stage of preclinical Alzheimer's disease.

Predicting outcome in mild cognitive impairment: 4-year follow-up study.

Background: Cognitive impairment precedes the diagnosis of Alzheimer's disease. It is unclear which psychometric measures predict dementia, and what cut-off points should be used. Replicable cognitive measures to provide information about differential diagnosis and prognosis would be clinically useful.